In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Study identifier:NIS-CLV-ATA-2008/1

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

In-practice Evaluation of Atacand 16mg Antihypertensive Effect

Medical condition

essential hypertension

Phase

-

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

400

Study type

Observational

Age

18 Years +

Date

Study Start Date: 01 Nov 2008
Primary Completion Date: 01 Jan 2009
Study Completion Date: 01 Jan 2009

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Jan 2015 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria